'Biohackers' go solo in quest to find cures (San Francisco Business Times)
'Supertemps' reshaping biotech workforce (Boston Business Journal)
Local life sciences companies are increasingly hiring workers — often those with high-level expertise — on a temporary, rather than a permanent, basis. (Boston Business Journal subscription required.)
Vertex and city celebrate topping off at Fan Pier (Boston Business Journal)
Developer Joseph Fallon, Mayor Thomas M. Menino and a crowd of construction workers watched as the final beam for the first of two Vertex Pharmaceuticals (Nasdaq: VRTX) office towers on Fan Pier was hoisted to the top of the 18-story building on Thursday. Work on the 1.1 million square foot global headquarters for Vertex is expected to be completed late next year.
Couple buys drug candidate, raising $25M betting it works (Triangle Business Journal)
Seed firms sprouting around UC Davis (Sacramento Business Journal)
Medtech startups increasing in Sacramento region (Sacramento Business Journal)
Human Genome Sciences' sale to GlaxoSmithKline: What it means for the D.C. area (Washington Business Journal)
Shower Shirt's sales volume nearly triples (Orlando Business Journal)
Mobile heart monitor doesn't skip a beat (San Francisco Business Times)
San Francisco-based AliveCor’s new iPhone electrocardiogram isn’t on the market yet, but it may have already saved a life. (San Francisco Business Times subscription required.)
Executive Profile: Astex Pharmaceutical CEO James Manuso (San Francisco Business Times)
Manuso, a self-described “Euro mutt,” joined SuperGen Inc. as a director in 2001 and became chairman and CEO of Astex Pharma after SuperGen’s acquisition last summer of Astex Therapeutics Ltd. in the U.K. The 140-employee company has three cancer drugs in mid-stage clinical trials, but the FDA in March rejected expanding its blood cancer drug Dacogen to elderly patients with acute myeloid leukemia. Manuso’s eclectic career has taken him from counseling heroin addicts in Bedford-Stuyvesant, part of his domestic service as a conscientious objector during the Vietnam War, to buying, fixing up and selling Manhattan properties. (San Francisco Business Times subscription required.)
Wake Forest Nano Center digging deeper to boost startups (The Business Journal)
Seeking to boost the pace of commercialization coming out of his labs at Wake Forest University, the director of the school’s Center for Nanotechnology and Molecular Materials has set up a partnership with an outside firm designed to mine early-stage research looking for potential money-makers. (The Business Journal subscription required.)
Drug maker donating to Franklin Institute brain exhibit (Philadelphia Business Journal)
Pharmaceutical giant Teva will donate $2.5 million toward the Franklin Institute’s fundraising campaign. The money will be put toward the museum’s planned “Your Brain” exhibit, which will explore neuroscience and the human brain.
Up close: Roger Cubicciotti (The Business Journal)
Roger Cubicciotti has lived and worked in biotech hotspots all over the country, but he chose the Piedmont Triad Research Park when it came time to settle his company, NanoMedica. Since arriving in 2010, Cubicciotti has also thrown his efforts behind building up fellow entrepreneurs and helping to organize the all-volunteer support group VentuRealization. (The Business Journal subscription required.)
Targacept exec to head biotech committee (The Business Journal)
Karen Hicks, the vice president of human resources at drug discovery firm Targacept, will chair the 24-member Advisory Committee for Biotechnology, under the auspices of N.C. Biotechnology Center.
Anthera seeks $33 million from stock offering (San Francisco Business Times)
Anthera Pharmaceuticals Inc. will use $33 million from the sale of 33 million shares for general corporate purposes, the company said Thursday.
CTRC tapped for clinical trial of ovarian cancer drug (San Antonio Business Journal)
Viral Genetics has selected the Cancer Therapy & Research Center at the University of Texas Health Science Center to conduct a Phase I clinical trial for an investigational ovarian cancer drug.